The recent Emergency Use Authorization issued by the Food and Drug Administration expands access to home collection testing for minors to allow a wider population to understand their health status and contain the spread of Coronavirus among children.
Following the May 2020 FDA EUA for the LetsGetChecked Coronavirus (COVID-19) home collection test and the March 2021 FDA EUA for direct-to-consumer purchasing without a prescription, this updated authorization for minors will support a safe return to school, play, travel, and more.
Using the company's end-to-end model, LetsGetChecked offers a FDA EUA authorized Coronavirus (COVID-19) home collection testing solution.
The Coronavirus (COVID-19) home collection test incorporates a nasal swab and PCR lab analysis with convenient and secure results in 24-72 hours after lab receipt. Unlike serology tests that detect the presence of antibodies or viral antigens, the test determines the presence or absence of SARS-CoV-2 viral RNA.
Under this re-issued LetsGetChecked authorization, children aged 12 to 18 years can self collect under adult supervision, and samples from children two to 11 years can be collected with adult assistance.
The ability to test minors for Coronavirus using LetsGetChecked's platform will provide parents and guardians increased peace of mind as the country reopens, and children gather in-person and return to the classroom.
LetsGetChecked is a virtual care company that allows customers to manage their health from home, providing direct access to telehealth services, pharmacy, and at-home diagnostics for a wide range of health conditions including Sexual Health, Cholesterol, Diabetes, Thyroid, Coronavirus (COVID-19), and more.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial